| pubmed-article:18339522 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18339522 | lifeskim:mentions | umls-concept:C0305065 | lld:lifeskim |
| pubmed-article:18339522 | lifeskim:mentions | umls-concept:C1704387 | lld:lifeskim |
| pubmed-article:18339522 | lifeskim:mentions | umls-concept:C1522642 | lld:lifeskim |
| pubmed-article:18339522 | lifeskim:mentions | umls-concept:C0282563 | lld:lifeskim |
| pubmed-article:18339522 | lifeskim:mentions | umls-concept:C1853126 | lld:lifeskim |
| pubmed-article:18339522 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:18339522 | lifeskim:mentions | umls-concept:C0037712 | lld:lifeskim |
| pubmed-article:18339522 | lifeskim:mentions | umls-concept:C0349590 | lld:lifeskim |
| pubmed-article:18339522 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18339522 | pubmed:dateCreated | 2008-6-16 | lld:pubmed |
| pubmed-article:18339522 | pubmed:abstractText | The prevalence and molecular epidemiology of pneumococcal macrolide resistance in South Africa was investigated. Minimum inhibitory concentrations and serotypes of pneumococcal isolates causing invasive disease from 2000-2005 (n=15982), collected through a national laboratory-based surveillance system, were determined. Randomly selected isolates from 2005 (51%; 260/508) had resistance mechanisms determined, and clonality was investigated by pulsed-field gel electrophoresis (PFGE) (n=64) and multilocus sequence typing (n=7). Macrolide resistance increased from 9% (160/1828) in 2000 to 14% (508/3656) in 2005 (P<0.001). Serotype 14 was the most common macrolide-resistant serotype (40%; 760/1921). The majority of macrolide-resistant isolates (75%; 1437/1921) displayed the macrolide-lincosamide-streptogramin B (MLS(B)) phenotype. Of the strains screened genotypically, 57% (147/260) contained erm(B), 27% (71/260) contained mef(A) and 15% (40/260) contained erm(B) and mef(A); 1% (2/260) contained ribosomal mutations. Macrolide-resistant isolates were predominantly penicillin-non-susceptible and multidrug-resistant. Isolates clustered according to serotype by PFGE, and 22% (14/64), 11% (7/64) and 5% (3/64) of isolates were related to the Taiwan(19F)-14, England(14)-9 and Spain(9V)-3 global clones, respectively. Routine use of the 7-valent pneumococcal conjugate vaccine (PCV-7) could reduce the burden of macrolide-resistant pneumococcal disease in South Africa. | lld:pubmed |
| pubmed-article:18339522 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18339522 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18339522 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18339522 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18339522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18339522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18339522 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18339522 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18339522 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18339522 | pubmed:issn | 0924-8579 | lld:pubmed |
| pubmed-article:18339522 | pubmed:author | pubmed-author:KlugmanKeith... | lld:pubmed |
| pubmed-article:18339522 | pubmed:author | pubmed-author:du... | lld:pubmed |
| pubmed-article:18339522 | pubmed:author | pubmed-author:von... | lld:pubmed |
| pubmed-article:18339522 | pubmed:author | pubmed-author:WolterNicoleN | lld:pubmed |
| pubmed-article:18339522 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:18339522 | pubmed:author | pubmed-author:Group for... | lld:pubmed |
| pubmed-article:18339522 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18339522 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:18339522 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18339522 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18339522 | pubmed:pagination | 62-7 | lld:pubmed |
| pubmed-article:18339522 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:meshHeading | pubmed-meshheading:18339522... | lld:pubmed |
| pubmed-article:18339522 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18339522 | pubmed:articleTitle | Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000-2005. | lld:pubmed |
| pubmed-article:18339522 | pubmed:affiliation | Respiratory and Meningeal Pathogens Research Unit, National Institute for Communicable Diseases, Medical Research Council and University of the Witwatersrand, Sandringham, South Africa. nicolew@nicd.ac.za | lld:pubmed |
| pubmed-article:18339522 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18339522 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:18339522 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18339522 | lld:pubmed |
